U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Sb
Molecular Weight 121.76
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANTIMONY

SMILES

[Sb]

InChI

InChIKey=OUULRIDHGPHMNQ-UHFFFAOYSA-N
InChI=1S/Sb.3H

HIDE SMILES / InChI

Molecular Formula Sb
Molecular Weight 121.76
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Antimony (Sb) is a toxic metalloid that occurs widely at trace concentrations in soil, aquatic systems, and the atmosphere. Antimony is not an abundant element but is found in small quantities in over 100 mineral species. It is most often found as antimony(III) sulfide. Antimony is used in the electronics industry to make some semiconductor devices, such as infrared detectors and diodes. It is alloyed with lead or other metals to improve their hardness and strength. A lead-antimony alloy is used in batteries. Other uses of antimony alloys include type metal (in printing presses), bullets and cable sheathing. Antimony has been in medical use against microbes and parasites as well. Antimony-based drugs have been prescribed against leishmaniasis since the parasitic transmission of the tropical disease was understood in the beginning of the 20th century. As a therapeutic, antimony has been mostly used for the treatment of leishmaniasis and schistosomiasis. The major toxic side-effects of antimonials as a result of therapy are cardiotoxicity (~9% of patients) and pancreatitis, which is seen commonly in HIV and visceral leishmaniasis co-infections.

Approval Year

PubMed

PubMed

TitleDatePubMed
Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
2015-09-15
Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis.
2011-01
[An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey].
2010-10
A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy.
2010-03
A case of visceral leishmaniasis in Oltenia region (Romania).
2010
Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.
2009-01
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors.
2007-09
Classification of heavy-metal toxicity by human DNA microarray analysis.
2007-05-15
Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
2004-09-24
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam.
2004-09-03
Functional identification of ion binding sites at the internal end of the pore in Shaker K+ channels.
2003-05-15
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
2002-05-02
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
2001-09-20
Cutaneous leishmaniasis in an Italian woman: case report.
2001-06
Leishmaniasis in Sudan. Mucosal leishmaniasis.
2001-04
Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.
2000-11
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
2000-11
[Hematologic characteristics of leishmaniasis].
2000-08-23
[American cutaneous leishmaniasis in the Federal District].
2000-07-06
Mucosal leishmaniasis: quantitative nasal cytology as a marker of disease activity and indicator of healing.
2000-01
Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction.
1999-05
Leishmaniasis of glans penis.
1998-05
Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil.
1997-10
Treatment of New World cutaneous and mucosal leishmaniases.
1996-09-01
[Clinical and pathogenetic features of exposure of workers to antimonate ore].
1996
Interleukin 6 during active visceral leishmaniasis and after treatment.
1995-10
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
1994-11-15
Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.
1994
[Interferon gamma as an immunological strategy for the treatment of human leishmaniasis].
1994
[Visceral leishmaniasis and multiple organ failure].
1993-12
Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent.
1991-03
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:43:49 GMT 2025
Edited
by admin
on Mon Mar 31 18:43:49 GMT 2025
Record UNII
9IT35J3UV3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANTIMONY
MI   WHO-DD  
Systematic Name English
ANTIMONY, ELEMENTAL
HSDB  
Preferred Name English
Antimony [WHO-DD]
Common Name English
STIBIUM METALLICUM [HPUS]
Common Name English
STIBIUM METALLICUM
HPUS  
Common Name English
SB
Code English
STIBIUM
Systematic Name English
C.I. 77050
Code English
PREPARED METALLIC ANTIMONY
Common Name English
ANTIMONY ELEMENT
Common Name English
ANTIMONY BLACK
Common Name English
ANTIMONY, ELEMENTAL [HSDB]
Common Name English
ANTIMONY [MI]
Common Name English
METALLIC ANTIMONY
Common Name English
Classification Tree Code System Code
DSLD 3349 (Number of products:23)
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
CFR 21 CFR 862.3110
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
NCI_THESAURUS C1940
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID5023879
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
CHEBI
30304
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
CHEBI
30513
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
MERCK INDEX
m1953
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB13110
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
MESH
D000965
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
RXCUI
1311407
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY RxNorm
PUBCHEM
5354495
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
HSDB
508
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
SMS_ID
100000077405
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
DAILYMED
9IT35J3UV3
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
FDA UNII
9IT35J3UV3
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
NCI_THESAURUS
C95187
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-146-5
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
EVMPD
SUB12914MIG
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
CAS
7440-36-0
Created by admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY